Insomnia News and Research

Latest Insomnia News and Research

Transcendental Meditation technique reduces PTSD symptoms in U.S. Marines

U.S. Marines and other active-duty military personnel who suffer from post-traumatic stress disorder (PTSD) are finding relief through a simple meditation technique known as the Transcendental Meditation (TM) technique.

29 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Medical cannabis can improve appetite, ease chronic pain, say researchers

Though controversial, medical cannabis has been gaining ground as a valid therapy, offering relief to suffers of diseases such as cancer, Post-Traumatic Stress Disorder, ALS and more.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Trial to evaluate whether zolpidem reduces suicidal thinking in depressed insomniacs

Researchers want to know whether a sleeping pill reduces suicidal thoughts in depressed patients with insomnia.

23 Jan 2013

Studies identify cellular pathways involved in governing day-night pattern of circadian rhythms

UC Irvine-led studies have revealed the cellular mechanism by which circadian rhythms - also known as the body clock - modify energy metabolism and also have identified novel compounds that control this action. The findings point to potential treatments for disorders triggered by circadian rhythm dysfunction, ranging from insomnia and obesity to diabetes and cancer.

23 Jan 2013

Daytime insomnia impact varies by subtype

Insomnia’s daytime impact appears to be greatest among those patients who have trouble both initiating and maintaining sleep, those with poor mental health, and those with childhood onset of the disorder, findings from the Great British Sleep Survey suggest.

14 Jan 2013

FDA requires sleep drugs that contain zolpidem to lower recommended doses

The U.S. Food and Drug Administration today announced it is requiring the manufacturers of Ambien, Ambien CR, Edluar and Zolpimist, widely used sleep drugs that contain the active ingredient zolpidem, to lower current recommended doses. Ambien and Ambien CR are also available as generics.

11 Jan 2013

Virtual patient can help future physicians more comfortable and capable assessing suicide risk

A virtual patient named Denise may help future physicians feel more comfortable and capable assessing suicide risk.

7 Jan 2013

Parkinson’s: an interview with Steve Ford, CEO of Parkinson’s UK

Parkinson’s disease is a neurological condition that is caused when brain cells, that produce the chemical messenger dopamine, start to die.

24 Dec 2012

Study: Half of the benefit of taking sleeping pills comes from the placebo effect

Half of the benefit of taking sleeping pills comes from the placebo effect, according to a major new study published in the British Medical Journal.

19 Dec 2012

Naurex announces completion of $38M Series B financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of a $38 million Series B financing led by new investor Baxter Ventures.

17 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Kessler's Northern New Jersey Traumatic Brain Injury System receives $2.2M NIDRR grant

The National Institute on Disability and Rehabilitation Research (NIDRR) of the U.S. Department of Education awarded a $2.2 million federal grant to Kessler Foundation.

13 Dec 2012

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.

12 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

IQWiG investigates benefits of rilpivirine for HIV treatment

Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).

8 Dec 2012